Where to buy Dorzox ?
- 2% w/v - Dorzolamide Hydrochloride USP;
- 0.5% w/v Timolol maleate IP;
- 0.0075%w/v Preservative Benzalkonium chloride NF;
- Aqueous vehicle;
Dorzox eye drops are indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or
ocular hypertension who are insufficiently responsive to beta-blockers.
Dorzox eye drops are contraindicated in patients with:
- A history of bronchial asthma;
- Bronchial asthma;
- Cardiogenic shock;
- Hypersensitivity to any component of Dorzox;
- Overt cardiac failure;
- Second or third degree atrioventricular block;
- Severe chronic obstructive pulmonary disease;
- Sinus bradycardia;
Dorzox eye drops dosage are 1 drop of Dorzox in the affected eye(s) 2 times daily.
If more than 1 topical ophthalmic medicine is being taking, the drugs should be administered at least 10 minutes apart.
There are no adequate and well-controlled studies in pregnant women. Dorzox eyr drops should be prescribed during pregnancy only if
the potential benefit justifies the potential risk to the fetus.
It is not known whether Dorzox eye drops are excreted in human milk. Dorzox has been detected in human milk following oral and
ophthalmic drug administration. Because of the potential for serious adverse reactions from Dorzox eye drops in nursing
infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the
importance of the medicine to the mother.
Dorzox eye drops fixed dose combination was evaluated for safety in 1000 patients with elevated intraocular pressure treated
for open-angle-glaucoma or ocular hypertension.
Approximately 6% of all patients discontinued therapy with Dorzox fixed dose combination because of undesirable effects. The
most frequently reported undesirable effects were taste perversion or ocular burning and/or stinging in up to 25% of patients.
4-14% of patients:
- Superficial punctate keratitis;
- Eye itching;
- Conjunctival hyperemia;
- Blurred vision;
The following undesirable effects were reported in 2-6% of patients:
- Vitreous detachment;
- Visual field defect;
- Urinary tract infection;
- Upper respiratory infection;
- Post-subcapsular cataract;
- Nuclear lens opacity;
- Lens opacity;
- Lens nucleus coloration;
- Glaucomatous cupping;
- Foreign body sensation;
- Eyelid pain or discomfort;
- Eyelid exudate/scales;
- Eyelid erythema;
- Eyelid edema;
- Eye tearing;
- Eye pain;
- Eye discharge;
- Eye debris;
- Dryness of eyes;
- Cortical lens opacity;
- Corneal staining;
- Corneal erosion;
- Conjunctival injection;
- Conjunctival follicles;
- Conjunctival edema;
- Conjunctival discharge;
- Cloudy vision;
- Back pain;
- Abdominal pain;
There are no human data available on overdosage with Dorzox fixed dose combination.
Symptoms consistent with systemic administration of beta-blockers or carbonic anhydrase inhibitors may occur, including:
- Cardiac arrest;
- Development of an acidotic state;
- Electrolyte imbalance;
- Possible central nervous system effects;
- Shortness of breath;
Dorzox eye drops are: a clear, colorless to nearly colorless, slightly viscous solution.
5ml vial available.